MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Glioblastoma (GBM) is the most common primary malignant brain tumor, with a universally poor prognosis. The emergence of molecular biomarkers has had a significant impact on histological typing and diagnosis, as well as predicting patient survival and response to treatment. The methylation status of the O6-methylguanine-DNA methyl-transferase (MGMT) gene promoter is one such molecular biomarker. Despite the strong evidence supporting the role of MGMT methylation status in prognostication, its routine implementation in clinical practice has been challenging. The methods and optimal cutoff definitions for MGMT status determination remain controversial. Variation in detection methods between laboratories presents a major challenge for consensus. Moreover, consideration of other clinical and genetic/epigenetic factors must also be incorporated into treatment decision making. In this review, we distill the available evidence to summarize our position on the optimal use of available assays, and propose strategies for resolving cases with equivocal methylation status and a framework for incorporating this important assay into research and clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationStupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationMGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationMethylation-specific PCR: a novel PCR assay for methylation status of CpG islands.
Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D., & Baylin, S. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.18.9821 · Cited by 5,646
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
DNA methylation-based classification of central nervous system tumours
Capper, D., Jones, D. T. W., Sill, M., Hovestadt, V., Schrimpf, D., Sturm, D., Koelsche, C., Sahm, F., Chavez, L., Reuss, D. E., et al. (2018) · Nature · doi:10.1038/nature26000 · Cited by 3,033
Self-citationA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834
Self-citationStupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Self-citationIdentification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Self-citationSturm, D., Witt, H., Hovestadt, V., Khuong-Quang, D.-A., Jones, D. T. W., Konermann, C., Pfaff, E., Tönjes, M., Sill, M., Bender, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.08.024 · Cited by 1,828
Self-citationMalmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacioglu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,286
Self-citationEsteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 1,253
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
Perry, J. R., Laperriere, N., O’Callaghan, C. J., Brandes, A. A., Menten, J., Phillips, C., Fay, M., Nishikawa, R., Cairncross, J. G., Roa, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611977 · Cited by 1,172
Self-citationWick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,135
Weller, M., van den Bent, M., Tonn, J. C., Stupp, R., Preusser, M., Cohen-Jonathan-Moyal, E., Henriksson, R., Rhun, E. L., Balana, C., Chinot, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30194-8 · Cited by 1,088
Self-citationDose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
Self-citationStupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052
Self-citationReporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
Altman, D. G., McShane, L. M., Sauerbrei, W., & Taube, S. E. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001216 · Cited by 1,013
Lomustine and Bevacizumab in Progressive Glioblastoma
Wick, W., Gorlia, T., Bendszus, M., Taphoorn, M., Sahm, F., Harting, I., Brandes, A. A., Taal, W., Domont, J., Idbaih, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707358 · Cited by 970
Self-citationEpidemiology of primary brain tumors: Current concepts and review of the literature
Wrensch, M., Minn, Y., Chew, T., Bondy, M., & Berger, M. S. (2002) · Neuro-Oncology · doi:10.1093/neuonc/4.4.278 · Cited by 837
Hegi, M. E., Liu, L., Herman, J. G., Stupp, R., Wick, W., Weller, M., Mehta, M. P., & Gilbert, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.5964 · Cited by 812
Self-citationWick, W., Hartmann, C., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M. C., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 809
Kaina, B., Christmann, M., Naumann, S., & Roos, W. P. (2007) · DNA Repair · doi:10.1016/j.dnarep.2007.03.008 · Cited by 663
Stupp, R., Taillibert, S., Kanner, A. A., Read, W. L., Steinberg, D. M., Lhermitte, B., Toms, S. A., Idbaïh, A., Ahluwalia, M. S., Fink, K., et al. (2017) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) · doi:10.5167/uzh-143757 · Cited by 630
Self-citationMGMT testing—the challenges for biomarker-based glioma treatment
Wick, W., Weller, M., van den Bent, M., Sanson, M., Weiler, M., von Deimling, A., Plass, C., Hegi, M., Platten, M., & Reifenberger, G. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.100 · Cited by 579
Self-citationWojdacz, T. K., & Dobrovic, A. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm013 · Cited by 551
Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A. A., Kantor, G., Taphoorn, M. J. B., Hassel, M. B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30313-8 · Cited by 495
Self-citationNygren, A. O. H. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni127 · Cited by 394
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts
Kitange, G. J., Carlson, B. L., Schroeder, M. A., Grogan, P. T., Lamont, J. D., Decker, P. A., Wu, W., James, C. D., & Sarkaria, J. N. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-090 · Cited by 390
Bady, P., Sciuscio, D., Diserens, A.-C., Bloch, J., van den Bent, M. J., Marosi, C., Dietrich, P.-Y., Weller, M., Mariani, L., Heppner, F. L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1016-2 · Cited by 344
Self-citationHovestadt, V., Remke, M., Kool, M., Pietsch, T., Northcott, P. A., Fischer, R., Cavalli, F. M. G., Ramaswamy, V., Zapatka, M., Reifenberger, G., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1126-5 · Cited by 292
van den Bent, M. J., Dubbink, H. J., Sanson, M., van der Lee-Haarloo, C. R., Hegi, M., Jeuken, J. W. M., Ibdaih, A., Brandes, A. A., Taphoorn, M. J. B., Frenay, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1034 · Cited by 255
Self-citationPredictive impact of MGMT promoter methylation in glioblastoma of the elderly
Reifenberger, G., Hentschel, B., Felsberg, J., Schackert, G., Simon, M., Schnell, O., Westphal, M., Wick, W., Pietsch, T., Loeffler, M., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27385 · Cited by 252
Qian, X. C., & Brent, T. P. (1997) · PubMed · Cited by 214
Quillien, V., Lavenu, A., Karayan‐Tapon, L., Carpentier, C., Labussière, M., Lesimple, T., Chinot, O., Wager, M., Honnorat, J., Saikali, S., et al. (2012) · Cancer · doi:10.1002/cncr.27392 · Cited by 212
Pérez-Larraya, J. G., Ducray, F., Chinot, O., Catry-Thomas, I., Taillandier, L., Guillamo, J.-S., Campello, C., Monjour, A., Cartalat-Carel, S., Barrie, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8086 · Cited by 212
Herrlinger, U., Schäfer, N., Steinbach, J. P., Weyerbrock, A., Hau, P., Goldbrunner, R., Friedrich, F., Rohde, V., Ringel, F., Schlegel, U., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4691 · Cited by 201
Vlassenbroeck, I., Califice, S., Diserens, A.-C., Migliavacca, E., Straub, J., Di Stefano, I., Moreau, F., Hamou, M.-F., Renard, I., Delorenzi, M., et al. (2008) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2008.070169 · Cited by 197
Self-citationWiestler, B., Capper, D., Sill, M., Jones, D. T. W., Hovestadt, V., Sturm, D., Koelsche, C., Bertoni, A., Schweizer, L., Korshunov, A., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1315-x · Cited by 194
Karayan-Tapon, L., Quillien, V., Guilhot, J., Wager, M., Fromont, G., Saikali, S., Etcheverry, A., Hamlat, A., Loussouarn, D., Campion, L., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0031-1 · Cited by 188
Jeuken, J. W. M., Cornelissen, S. J. B., Vriezen, M., Dekkers, M. M. G., Errami, A., Sijben, A., Boots-Sprenger, S. H. E., & Wesseling, P. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700664 · Cited by 180
Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas
Everhard, S., Tost, J., El Abdalaoui, H., Crinière, E., Busato, F., Marie, Y., Gut, I. G., Sanson, M., Mokhtari, K., Laigle-Donadey, F., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-001 · Cited by 177
Wick, W., Gorlia, T., Bady, P., Platten, M., van den Bent, M. J., Taphoorn, M. J. B., Steuve, J., Brandes, A. A., Hamou, M.-F., Wick, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3153 · Cited by 159
Self-citationBady, P., Delorenzi, M., & Hegi, M. E. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.11.009 · Cited by 157
Self-citationMalley, D. S., Hamoudi, R., Kocialkowski, S., Pearson, D. M., Collins, V. P., & Ichimura, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0803-5 · Cited by 152
Christians, A., Hartmann, C., Benner, A., Meyer, J., von Deimling, A., Weller, M., Wick, W., & Weiler, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033449 · Cited by 146
van den Bent, M. J., Erdem-Eraslan, L., Idbaih, A., de Rooi, J., Eilers, P. H. C., Spliet, W. G. M., den Dunnen, W. F. A., Tijssen, C., Wesseling, P., Sillevis Smitt, P. A. E., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1157 · Cited by 121
Lalezari, S., Chou, A. P., Tran, A. N., Solis, O. E., Khanlou, N., Chen, W., Li, S., Carrillo, J., Chowdhury, R., Selfridge, J. M., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos308 · Cited by 116
Shah, N., Lin, B., Sibenaller, Z. A., Ryken, T. C., Lee, H., Yoon, J., Rostad, S. W., & Foltz, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016146 · Cited by 112
Hegi, M. E., & Stupp, R. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov198 · Cited by 112
Self-citationBell, E. H., Pugh, S. L., McElroy, J. P., Gilbert, M. R., Mehta, M. P., Klimowicz, A. C., Magliocco, A. M., Bredel, M., Robe, P. A. J. T., Grosu, A., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6020 · Cited by 107
Self-citationHegi, M. E., Janzer, R.-C., Lambiv, W. L., Gorlia, T., Kouwenhoven, M. C. M., Hartmann, C. J., von Deimling, A., Martinet, D., Schmutz, N. B., Diserens, A., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0938-4 · Cited by 93
Self-citationBady, P., Kurscheid, S., Delorenzi, M., Gorlia, T., van den Bent, M. J., Hoang‐Xuan, K., Vauléon, É., Gijtenbeek, A., Enting, R. H., Thiessen, B. A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1810-6 · Cited by 91
Self-citationSciuscio, D., Diserens, A.-C., van Dommelen, K., Martinet, D., Jones, G., Janzer, R.-C., Pollo, C., Hamou, M.-F., Kaina, B., Stupp, R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1931 · Cited by 84
Self-citationThe Role of MGMT Testing in Clinical Practice
Cankovic, M., Nikiforova, M. N., Snuderl, M., Adesina, A. M., Lindeman, N. I., Wen, P. Y., & Lee, E. Q. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.05.011 · Cited by 76
Self-citationBrigliadori, G., Foca, F., Dall’Agata, M., Rengucci, C., Melegari, E., Cerasoli, S., Amadori, D., Calistri, D., & Faedi, M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2116-y · Cited by 70
Understanding and manipulating O6-methylguanine-DNA methyltransferase expression
Pieper, R. O. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00003-x · Cited by 69
Switzeny, O. J., Christmann, M., Renovanz, M., Giese, A., Sommer, C., & Kaina, B. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0204-7 · Cited by 67
Quillien, V., Lavenu, A., Ducray, F., Joly, M., Chinot, O. L., Fina, F., Sanson, M., Carpentier, C., Karayan, L., Rivet, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11322 · Cited by 65
Bienkowski, M., Berghoff, A. S., Marosi, C., Wöhrer, A., Heinzl, H., Hainfellner, J. A., & Preusser, M. (2015) · Clinical Neuropathology · doi:10.5414/np300904 · Cited by 57
The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment
Janes, H., PEPE, M. S., McShane, L. M., Sargent, D. J., & Heagerty, P. J. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv157 · Cited by 40
Aldape, K., Nejad, R., Louis, D. N., & Zadeh, G. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now181 · Cited by 33
Self-citationPrognosis of glioblastoma with faint MGMT methylation-specific PCR product
Hsu, C., Ho, H., Lin, S., Chang‐Chien, Y., Chen, M.-H., Hsu, S. P. C., Yen, Y., Guo, W.-Y., & Ho, D. M. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1701-1 · Cited by 27
Lee, A., Youssef, I., Osborn, V. W., Safdieh, J. J., Becker, D. J., & Schreiber, D. P. (2018) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2018.02.009 · Cited by 27
Trabelsi, S., Mama, N., Ladib, M., Karmeni, N., Mastouri, M. H., Chourabi, M., Mokni, M., Tlili, K., Krifa, H., Yacoubi, M. T., et al. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1381-0 · Cited by 15
Cited by
Artificial intelligence in cancer imaging: Clinical challenges and applications
Bi, W. L., Hosny, A., Schabath, M. B., Giger, M. L., Birkbak, N. J., Mehrtash, A., Allison, T., Arnaout, O., Abbosh, C., Dunn, I. F., et al. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21552 · Cited by 1,846
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 704
MGMT Status as a Clinical Biomarker in Glioblastoma
Butler, M., Pongor, L., Su, Y.-T., Xi, L., Raffeld, M., Quezado, M., Trepel, J., Aldape, K., Pommier, Y., & Wu, J. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.010 · Cited by 342
Self-citationPrognostic and Predictive Biomarkers in Gliomas
Śledzińska, P., Bebyn, M. G., Furtak, J., Kowalewski, J., & Lewandowska, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910373 · Cited by 340
Tomar, M. S., Kumar, A., Srivastava, C., & Shrivastava, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188616 · Cited by 325
Metadata
- Authors
- Mansouri, A., Hachem, L. D., Mansouri, S., Nassiri, F., Laperriere, N. J., Xia, D., Lindeman, N. I., Wen, P. Y., Chakravarti, A., Mehta, M. P., Hegi, M. E., Stupp, R., Aldape, K. D., & Zadeh, G.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-09-05
- Volume
- 21
- Issue
- 2
- Pages
- 167-178
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2891484912
- Cited by
- 340
- References
- 65
- FWCI
- 12.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.